[Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure]

[Article in Spanish]

C S Kow¹, D S Ramachandram², S S Hasan^{3

4}

Affiliations

¹ School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malasia.
² School of Pharmacy, Monash University Malaysia, Bandar Sunway, Subang Jaya, Selangor, Malasia.
³ School of Applied Sciences, University of Huddersfield, Huddersfield, Reino Unido.
⁴ School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia.

[Article in Spanish]

C S Kow et al. Rev Clin Esp. 2022 May.

. 2022 May;222(5):309-310.

doi: 10.1016/j.rce.2021.11.002. Epub 2021 Nov 20.

C S Kow¹, D S Ramachandram², S S Hasan^{3

4}

¹ School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malasia.
² School of Pharmacy, Monash University Malaysia, Bandar Sunway, Subang Jaya, Selangor, Malasia.
³ School of Applied Sciences, University of Huddersfield, Huddersfield, Reino Unido.
⁴ School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia.

No abstract available

Cited by

[Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence].
Salinas-Botrán A, Pérez-Belmonte LM, Méndez-Bailón M; en representación del grupo SEMI-COVID-19 Network. Salinas-Botrán A, et al. Rev Clin Esp. 2022 May;222(5):310-311. doi: 10.1016/j.rce.2021.11.001. Epub 2021 Nov 20. Rev Clin Esp. 2022. PMID: 34840339 Free PMC article. Spanish. No abstract available.
Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence.
Salinas-Botrán A, Pérez-Belmonte LM, Méndez-Bailón M; en representación del grupo SEMI-COVID-19 Network. Salinas-Botrán A, et al. Rev Clin Esp (Barc). 2022 May;222(5):310-311. doi: 10.1016/j.rceng.2021.11.001. Epub 2022 Jan 24. Rev Clin Esp (Barc). 2022. PMID: 35101382 Free PMC article. No abstract available.

1. Salinas-Botrán A., Sanz-Cánovas J., Pérez-Somarriba J., Pérez-Belmonte L.M., Cobos-Palacios L., Rubio-Rivas M., et al. Características clínicas y factores de riesgo al ingreso de mortalidad en pacientes con insuficiencia cardíaca hospitalizados por COVID-19 en España. Rev Clin Esp. 2022;222:255–265. - PMC - PubMed
1. Dessie Z.G., Zewotir T. Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21:855. - PMC - PubMed
1. Zhang L., Hou J., Ma F.Z., Li J., Xue S., Xu Z.G. The common risk factors for progression and mortality in COVID-19 patients: A meta-analysis. Arch Virol. 2021;166:2071–2087. - PMC - PubMed
1. Becker D.E. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 2013;60:25–32. - PMC - PubMed
1. Pérez-Belmonte L.M., Sanz-Cánovas J., Salinas A., Sagastagoitia Fornie I., Méndez-Bailón M., Gómez-Huelgas R., et al. Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: A multicenter retrospective study. Intern Emerg Med. 2021;16:2301–2305. - PMC - PubMed